Business
NRF backs glaucoma biotech PolyActiva’s $40 million Series C
The federal Labor government’s flagship National Reconstruction Fund Corporation (NRFC) is back investing post-election, hitting the send button on another $27 million to lead a $40 million Series C for PolyActiva. The 15-year-old Melbourne biotechnology scaleup is developing potentially revolutionary eye implant technology to treat glaucoma and improve treatment outcomes for patients with ocular (eye)… Read more »
